Back | Next |
home / stock / veru / veru message board
Subject | By | Source | When |
---|---|---|---|
Yes, that is very suspicious. | Gman3343 | investorshub | 11/12/2022 12:32:33 AM |
Here Today, | Alleyba1 | investorshub | 11/11/2022 8:58:35 PM |
I agree with you, but I think, in | Alleyba1 | investorshub | 11/11/2022 8:55:07 PM |
Accumulate here. | klarino man | investorshub | 11/11/2022 5:16:01 PM |
Not over yet since the FDA May allow | Here Today | investorshub | 11/11/2022 4:26:22 PM |
Veru got screwed by the FDA. They didn't | Gman3343 | investorshub | 11/11/2022 2:51:02 PM |
This seems reasonable. Took a lotto premarket in | frankyahoo | investorshub | 11/11/2022 1:56:35 AM |
Oppenheimer analyst Leland Gershell maintains Veru, Inc. at | rwwest | investorshub | 11/11/2022 1:09:45 AM |
Alleyba1 In my opinion, Dr. Mario Eisenbarger, who was | Alleyba1 | investorshub | 11/10/2022 1:29:29 PM |
FDA will fuckkk every one , | Lolo12 | investorshub | 11/10/2022 1:08:47 PM |
Blood bath in here now. | Gman3343 | investorshub | 11/10/2022 12:23:54 PM |
I'm not a fan either, but I won't | Gman3343 | investorshub | 11/10/2022 2:58:50 AM |
Thank you. I will check it out. Not | frankyahoo | investorshub | 11/10/2022 2:52:31 AM |
Damn, if he only waited. I'm not selling. | Gman3343 | investorshub | 11/10/2022 2:50:07 AM |
My buddy bought $VERU puts on Monday with | frankyahoo | investorshub | 11/10/2022 2:41:18 AM |
Oh, and the FDA let's all the crap | Gman3343 | investorshub | 11/10/2022 2:32:00 AM |
My options are going to shyt. Unbelievable these | Gman3343 | investorshub | 11/10/2022 2:29:06 AM |
Karma, Steiner... KARMA!! | nonsequetor | investorshub | 11/10/2022 12:45:35 AM |
Sorry to hear you got stuck. All the | frankyahoo | investorshub | 11/09/2022 11:41:05 PM |
The FDA does not have to follow what | Alleyba1 | investorshub | 11/09/2022 11:30:37 PM |
News, Short Squeeze, Breakout and More Instantly...
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innov...
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it ...
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 -- MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical ...